The Trade Desk to Release Q3 Earnings: Key Factors to Watch

The Trade Desk is due to report Q3 2026 results on Nov. 9; consensus calls for revenue of $650.7 million, down 12% year over year, and EPS of 26 cents, down 42.2%. Advertising-budget pressure, a forecast of no meaningful macro improvement, and a planned workforce reduction of approximately 15% weigh on the outlook; restructuring charges are estimated at $39 million to $51 million, partly offset by a $4 million to $5 million stock-compensation reversal. CTV, retail media, advertiser partnerships and AI tools offer support, but the company’s shares have fallen 73.1% over the past year.

Analysis

The setup is less about whether TTD clears a low bar than whether buyers believe the operating model can absorb slower ad demand without sacrificing platform investment. A clean revenue result paired with weak EBITDA conversion would not resolve that concern; the restructuring may lower the cost base, but its cash and GAAP charges complicate the quarter and do not establish sustainable savings. Treat management’s initial AI performance claims as unproven until adoption, retention, and advertiser economics are disclosed.

Near term, the Nov. 9 print can drive a sharp repricing in either direction after the stock’s substantial derating, but neither the article nor supplied data establish valuation or options pricing. Over 1–3 months, watch forward growth commentary, expense trajectory, and evidence that execution issues are receding. Over 6–18 months, CTV and retail-media expansion can support growth, while retailer-owned ad platforms and large-platform buying tools could capture budgets that otherwise flow through independent DSPs. A tougher consumer backdrop may also shift spend toward channels advertisers can directly tie to sales, making measurement credibility—not AI branding—the key competitive test.

Contrarian read: the long-run CTV opportunity is real, but it may already be familiar to investors; the more consequential surprise would be renewed growth and margin discipline. IQVIA and Veeva integrations are strategic capability signals, not evidence of material near-term revenue contribution absent disclosure. Falsifiers: revenue below management’s floor, adjusted EBITDA below its indicated level, or further deterioration in forward growth would undermine stabilization; sustained growth with improving EBITDA conversion would challenge the bearish case.

Key Decisions for Investors

• Avoid an unhedged pre-earnings directional position; the event offers asymmetric gap risk and the provided information is insufficient to assess valuation or implied volatility.
• Post-print, consider a staged TTD long only if revenue meets or exceeds management’s floor, adjusted EBITDA is at least around its indicated level, and forward commentary implies improving growth or expense leverage. Invalidate on a subsequent guide-down or renewed margin deterioration.
• If revenue falls below the company’s floor or EBITDA misses its indicated level and management signals continued execution problems, consider a defined-risk bearish TTD position after the open rather than assuming the prior selloff has priced in the downside.
• Track quarterly advertiser retention/spend, CTV and retail-media growth, and operating-expense growth versus revenue. Treat IQVIA and Veeva as possible beneficiaries of broader healthcare measurement adoption, but do not trade them on this announcement without evidence of incremental financial contribution.